| 000 | 01610cam a2200157 4500500 | ||
|---|---|---|---|
| 005 | 20251012013221.0 | ||
| 041 | _afre | ||
| 042 | _adc | ||
| 100 | 1 | 0 |
_aAujard, Yannick _eauthor |
| 245 | 0 | 0 | _aBacterial meningitis in newborns |
| 260 | _c2025. | ||
| 500 | _a51 | ||
| 520 | _aBacterial meningitis in newborns is usually secondary to a bacterial translocation from the digestive tract to the bloodstream. The risk of meningeal invasion depends on: 1) specific virulence genes; 2) the bacterial load in the bloodstream; and 3) the level of humoral and cellular immune defenses. The initial bacteremia may also invade brain tissue or the subdural space, causing abscesses and/or empyemas. Lumbar puncture is performed based on clinical and biological risk factors but is not routinely indicated. Empiric antibiotic therapy must be bactericidal. In France, a combination of amoxicillin, cefotaxime, and an aminoglycoside is the most commonly used treatment until the pathogen is identified. Ciprofloxacin, which targets Gram-negative bacteria, and rifampicin, used against GBS, are treatments for brain abscesses. They can be added to the initial antibiotic therapy based on brain MRI results obtained after 5 to 7 days of treatment. The prognosis of bacterial meningitis in newborns is severe, with a mortality rate of 10% and neurological sequelae occurring in 25 to 50% of cases. | ||
| 786 | 0 | _nMédecine thérapeutique / Pédiatrie | 26 | 2 | 2025-04-15 | p. 107-116 | 1286-5494 | |
| 856 | 4 | 1 | _uhttps://shs.cairn.info/journal-medecine-therapeutique-pediatrie-2024-2-page-107?lang=en&redirect-ssocas=7080 |
| 999 |
_c1528783 _d1528783 |
||